高流动性组盒子1通过调节巨细胞来减轻膜化,减轻大动脉狭窄
Dong Zhao1, Yun Zhao1, Li-Na Luan1
1Shanghai Geriatric Medical Centre, Shanghai, China.
概括
高流动性组盒子1 (HMGB1) 可能抑制炎症并减少状大动脉病 (CAVD) 的进展. 在严重的CAVD患者中,HMGB1水平较低,这表明大动脉狭窄的治疗潜力.
科学领域:
- 生物化学 生物化学
- 免疫学 免疫学 免疫学
- 心血管研究研究心血管研究
背景情况:
- 动脉疾病 (CAVD) 涉及巨细胞透和膜化.
- 之前的研究表明,高流动性组盒1 (HMGB1) 可能抑制M1巨细胞两极分化并减轻CAVD进展.
- 在巨细胞介导的膜化中HMGB1的确切作用需要进一步研究.
研究的目的:
- 探索HMGB1在调节CAVD中巨细胞介导的膜化中的作用.
- 调查CAVD患者的HMGB1水平及其与疾病严重程度的关联.
- 检查HMGB1对巨细胞介导化在共同培养系统中的影响.
主要方法:
- 从健康个人和CAVD患者的血清样本使用ELISA进行了分析.
- 在人类心脏组织阵列中,免疫光染色评估了巨细胞透 (CD68).
- 使用巨细胞和大动脉间歇细胞 (haVICs) 的共同培养系统来评估HMGB1对化标志物 (RUNX2,骨质,ALP) 的影响.
主要成果:
- 与对照组相比,在严重的CAVD患者中,HMGB1血清水平显著降低.
- 在化门中增加的CD68表达证实了巨细胞透.
- 接受HMGB1治疗的巨细胞减少了haVICs中的RUNX2mRNA表达和性酸酶 (ALP) 活性,表明抑制了化.
结论:
- 在严重的CAVD中,HMGB1水平下降,这表明它起着保护作用.
- HMGB1通过调节巨细胞和HAVIC相互作用,对膜化产生潜在的抑制作用.
- HMGB1可以作为缓解炎症和大动脉狭窄症进展的治疗点.
更多相关视频
相关概念视频
Mitral Stenosis III: Medical Management
247
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
247
Antihypertensive Drugs: Action of Calcium Channel Blockers
1.5K
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
1.5K
Atherosclerosis III: Management
322
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
322
Aortic Regurgitation III: Medical Management
399
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
399


